Evolving Market Trends In The Irritable Bowel Syndrome (IBS) Treatment Industry: Ardelyx Breaks Ground With Ibsrela, A First-In-Class Treatment For Irritable Bowel Syndrome With Constipation (IBS-C)

The Irritable Bowel Syndrome (IBS) Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Irritable Bowel Syndrome (IBS) Treatment Market Size During the Forecast Period?
The market size for the treatment of irritable bowel syndrome (IBS) has seen rapid expansion in recent years. The market is projected to increase from $2.79 billion in 2024 to $3.07 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.2%. The notable growth during the historic period is due to several factors including the rising prevalence of IBS, improved patient awareness, lifestyle and stress factors, the influence of patient advocacy and support groups, and favorable healthcare reimbursement policies.

The market size for the treatment of irritable bowel syndrome (IBS) is anticipated to witness substantial progress over the coming years, with a predicted surge to $4.93 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. Factors contributing to this growth during the forecast period include the adoption of patient-focused healthcare models, advancements in microbial therapies, the application of blockchain in healthcare, patient-reported outcomes (pros), streamlined regulatory programs, and improved health data compatibility. Key trends expected during this period encompass the incorporation of digital health solutions, forward strides in diagnostic technologies, rising investments in research and development, industry partnerships and collaborations, and the introduction of non-drug therapies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11978

What Are the High-Growth Segments in the Irritable Bowel Syndrome (IBS) Treatment Market?
The irritable bowel syndrome (IBS) treatment market covered in this report is segmented -

1) By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings

Subsegments:
1) By Lubiprostone: Chronic Idiopathic Constipation Treatment, Irritable Bowel Syndrome with Constipation (IBS-C) Treatment
2) By Linaclotide: IBS-C Treatment, Chronic Idiopathic Constipation Treatment
3) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment
4) By Rifaximin: IBS-D Treatment, Small Intestinal Bacterial Overgrowth (SIBO) Treatment
5) By Alosetron: Severe IBS-D Treatment for Women
6) By Other Drugs: Prucalopride, Tenapanor, Plecanatide

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp

What Key Drivers Are Expected to Influence Future Irritable Bowel Syndrome (IBS) Treatment Market Growth?
The increase in the number of cases of irritable bowel syndrome (IBS), a chronic gastrointestinal disorder that affects the large intestine, is anticipated to boost the growth of the market for its treatment. Various factors such as unhealthy lifestyles, improper dietary practices, exposure to pollutants and heightened stress levels are contributing to the surge in IBS cases. IBS treatments are beneficial in minimizing the frequency and severity of IBS symptoms, enhancing life quality, and assisting individuals in handling their conditions more effectively. As per the International Foundation for Gastrointestinal Disorders (IFFGD), a non-profit educational and research organization based in the US, roughly 5-10% of the global population in 2023 and 25 to 45 million individuals in the USA are affected by IBS. As a result, the increased prevalence of IBS is fostering the expansion of the IBS treatment market.

Which Companies Hold the Largest Share Across Different Irritable Bowel Syndrome (IBS) Treatment Market Segments?
Major companies operating in the irritable bowel syndrome (IBS) treatment market include Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Cosmo Technologies Ltd., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc.

What Trends Are Driving Growth in The Irritable Bowel Syndrome (IBS) Treatment Market?
In the irritable bowel syndrome (IBS) market, the emergence of product innovations is a prominent trend. A number of key players in the IBS market are focusing on generating novel and advanced products in order to secure their market standing. For example, Ardelyx, a biotechnology corporation based in the US, unveiled IBSRELA, a pioneering IBS-C treatment for adults, in April 2022. This is the singular NHE3 inhibitor accessible for the treatment of adults diagnosed with irritable bowel syndrome and constipation (IBS-C). IBSRELA, which is Ardelyx's maiden FDA-approved medication, represents the first unique mechanism therapy for IBS-C that has been introduced in nearly a decade. It offers a substantial new alternative for treating constipation, bloating, and abdominal pain, which are symptomatic of this debilitating condition.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

What Are the Emerging Geographies for The Irritable Bowel Syndrome (IBS) Treatment Market Growth?
North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (IBS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Irritable Bowel Syndrome (IBS) Treatment Market?
2. What is the CAGR expected in the Irritable Bowel Syndrome (IBS) Treatment Market?
3. What Are the Key Innovations Transforming the Irritable Bowel Syndrome (IBS) Treatment Industry?
4. Which Region Is Leading the Irritable Bowel Syndrome (IBS) Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.